Sunesis Pharmaceuticals Inc. (Nasdaq: SNSS) stock surged again by soaring 33 cents to close at $1.72 after the company reported upbeat clinical trial data for its cancer treatment Voreloxin earlier this week.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.